<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6291">
  <stage>Registered</stage>
  <submitdate>20/01/2017</submitdate>
  <approvaldate>20/01/2017</approvaldate>
  <nctid>NCT03029780</nctid>
  <trial_identification>
    <studytitle>An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma</studytitle>
    <scientifictitle>Phase II, Randomized, Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma</scientifictitle>
    <utrn />
    <trialacronym>CheckMate 800</trialacronym>
    <secondaryid>CA209-800</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Renal Cell Carcinoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Non melanoma skin cancer</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Kidney</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - Opdivo
Other interventions - Yervoy

Experimental: Co-Administration - Nivolumab and Ipilimumab Co-Administration

Experimental: Sequential Administration - Nivolumab and Ipilimumab Sequential Administration


Other interventions: Opdivo
Specified dose on specified days

Other interventions: Yervoy
Specified dose on specified days

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of adverse events (AEs) in anaphylactic reaction SMQ (Standardized Medical Dictionary for Regulatory Activities Queries) - Broad Scope</outcome>
      <timepoint>Up to 20 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of AEs in anaphylactic reaction SMQ (Standardized Medical Dictionary for Regulatory Activities Queries) - Narrow Scope</outcome>
      <timepoint>Up to 20 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of grade 3-5 AEs - measured by number of pateints</outcome>
      <timepoint>Up to 20 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Nivolumab as measured using serum concentration- time data - Predose</outcome>
      <timepoint>Up to 16 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Nivolumab as measured using serum concentration- time data - End of infusion</outcome>
      <timepoint>Up to 10 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ipilimumab as measured using serum concentration- time data - Predose</outcome>
      <timepoint>Up to 16 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ipilimumab as measured using serum concentration- time data - End of infusion</outcome>
      <timepoint>Up to 10 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Anti-nivolumab antibody - measured by immunoassay</outcome>
      <timepoint>Up to 20 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Anti-ipilimumab antibody - measured by immunoassay</outcome>
      <timepoint>Up to 20 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Maximum observed serum concentration (Cmax) - End of Infusion</outcome>
      <timepoint>Up to 10 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Objective Response Rate (ORR) - measured by time</outcome>
      <timepoint>Up to 20 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression Free Survival (PFS) - measured by number of patients</outcome>
      <timepoint>Up to 20 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        

          -  Advanced Renal Cell Carcinoma

          -  Must have full activity or, if limited, must be able to walk and carry out light
             activities such as light house work or office work

          -  Must have at least 1 lesion with measurable disease</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Subjects with active central nervous system metastases

          -  Subjects who received prior therapy with checkpoint inhibitor

          -  Subjects with active, known or suspected autoimmune disease

        Other protocol defined inclusion/exclusion criteria could apply</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>9/02/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>21/02/2021</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC</recruitmentstate>
    <hospital>Local Institution - Waratah</hospital>
    <hospital>Local Institution - Westmead</hospital>
    <hospital>Local Institution - Herston</hospital>
    <hospital>Local Institution - Elizabeth Vale</hospital>
    <hospital>Local Institution - Malvern</hospital>
    <postcode>2298 - Waratah</postcode>
    <postcode>2145 - Westmead</postcode>
    <postcode>4029 - Herston</postcode>
    <postcode>5112 - Elizabeth Vale</postcode>
    <postcode>3144 - Malvern</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Metropolitana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Santiago de Chile</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bristol-Myers Squibb</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate safety and efficacy of different administration
      regimens of nivolumab plus ipilimumab in subjects with renal cell carcinoma.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03029780</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bristol-Myers Squibb</name>
      <address>Bristol-Myers Squibb</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</name>
      <address />
      <phone>please email:</phone>
      <fax />
      <email>Clinical.Trials@bms.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>